Keytruda® (pembrolizumab) – New warnings
July 27, 2017 – The FDA approved updates to the Warnings and Precautions section of the Keytruda (pembrolizumab) drug label regarding immune-mediated skin adverse reactions and other immune-mediated adverse reactions to include solid organ transplant rejection.
Top